Rznomics Inc
476830
Company Profile
Business description
Rznomics Inc is engaged in research and development of biopharmaceuticals, developing gene therapy drugs based on RNA substitution enzyme platform and self-cycling RNA platform technologies, and commercializing them through technology transfer.
Contact
Pangyo Innovalley, 253 Pangyo-ro
801, C Building
Bundang-gu
Gyeonggi-do
Seongnam-si
KORT: +82 317068730
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,245.80 | 18.07 | -0.22% |
| DAX 40 | 23,806.99 | 273.64 | -1.14% |
| Dow JONES (US) | 48,228.45 | 318.53 | 0.66% |
| FTSE 100 | 10,603.48 | 5.40 | -0.05% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,828.78 | 193.79 | 0.86% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,827.95 | 45.14 | 0.67% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |